8-K: IN8bio Receives Nasdaq Extension for Minimum Bid Price Compliance, Announces Annual Meeting Date

IN8bio, Inc. received an extension from Nasdaq to regain compliance with the minimum bid price rule and announced the date for its 2025 Annual Meeting of Stockholders.

Summary

• IN8bio, Inc. received an extension from Nasdaq until August 4, 2025, to regain compliance with the minimum closing bid price requirement of $1.00 per share.
• The company's common stock listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective February 7, 2025.
• If the stock price reaches at least $1.00 for 10 consecutive business days before August 4, 2025, Nasdaq will confirm compliance.
• Failure to comply by August 4, 2025, may result in delisting, which the company can appeal.
• IN8bio intends to monitor its stock price and consider options like a reverse stock split to regain compliance.
• The 2025 Annual Meeting of Stockholders will be held on May 8, 2025.
• The record date for determining stockholders entitled to notice of and to vote at the 2025 Annual Meeting will be the close of business on March 12, 2025.
• Stockholder proposals for inclusion in proxy materials must be received by February 17, 2025.
• Stockholder director nominations must be received by February 17, 2025.
• Notice to the Company from stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must be provided no later than March 9, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the non-compliance with Nasdaq's listing requirements, but the extension provides an opportunity for the company to improve its situation. The potential need for a reverse stock split adds to the negative sentiment.

Positives

• Nasdaq granted IN8bio an extension to regain compliance with the minimum bid price rule, providing more time to improve its stock price.
• The company is actively considering options, including a reverse stock split, to address the deficiency.

Negatives

• IN8bio's common stock is not in compliance with Nasdaq's minimum bid price requirement.
• The company's stock listing was transferred to the Nasdaq Capital Market, which typically has less stringent requirements than the Global Market.
• Failure to regain compliance by August 4, 2025, could lead to delisting from Nasdaq.

Risks

• There is a risk that IN8bio will not be able to regain compliance with the minimum bid price requirement by August 4, 2025, potentially leading to delisting.
• The company may need to implement a reverse stock split, which could negatively impact shareholder value.
• The company's stock price may continue to decline, making it difficult to meet the minimum bid price requirement.

Future Outlook

IN8bio intends to actively monitor its stock price and consider available options, including a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, especially during periods of market volatility or when clinical trial results are delayed or disappointing. Receiving an extension is a common occurrence, but the company must take decisive action to improve its stock price and investor confidence.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with Nasdaq compliance.
• Companies like Celldex Therapeutics and Ziopharm Oncology have faced similar situations and implemented reverse stock splits to regain compliance.
• The success of these strategies depends on the company's ability to execute its business plan and achieve positive clinical trial results.

Stakeholder Impact

• Shareholders face the risk of delisting and potential dilution from a reverse stock split.
• Employees may experience uncertainty due to the company's financial situation.
• The company's ability to raise capital and fund its research and development programs could be affected.

Next Steps

• IN8bio will monitor its stock price.
• IN8bio will consider options to resolve the deficiency, including a reverse stock split.
• IN8bio will prepare for the 2025 Annual Meeting of Stockholders.

Key Dates